ASX-listed MGC Pharma is the first medical cannabis producer to float on the main board of the London Stock Exchange, as Australian players rush into the rapidly opening European market.

https://www.afr.com/companies/healthcare-and-fitness/aussie-cannabis-players-blaze-a-trail-in-europe-20210210-p5712u

https://stockhead.com.au/health/mgc-pharma-makes-strong-debut-as-london-stock-exchanges-first-medicinal-cannabis-company/

- MGC Pharmaceuticals (MXC) has appointed Nicole Godresse as Global Chief Sales Officer, effective immediately
- Nicole has more than 20 years experience in the pharmaceutical and healthcare industries, having worked with the likes of Johnson & Johnson and Eli Lilly
- Her most recent role at Tilray saw her play a part in launching the first medical cannabis brand legally in Australia and New Zealand
- She also helped launch one of the first medical cannabis clinics in the country and deliver some of Australia's first government-funded medical cannabis trials

https://themarketherald.com.au/mgc-pharmaceuticals-asxmxc-appoints-nicole-godresse-as-global-chief-sales-officer-2021-01-13/

Nicole's target (KPI) is for MGC Pharmaceuticals to reach $1million in sales per month.

https://www.proactiveinvestors.com.au/companies/news/939936/mgc-pharma-s-new-head-of-global-sales-has-big-ambitions-and-says-they-re--ready-to-go--939936.html

- MGC Pharmaceuticals (MXC) is set to become the first medicinal cannabis company to be admitted to the main market of the London Stock Exchange.

- The company will join the LSE on February 9 after a strongly supported placement was completed and £6.5 million (around A$12 million) was raised.


https://themarketherald.com.au/mgc-pharmaceuticals-asxmxc-to-list-on-lse-next-week-2021-02-04/

https://prohibitionpartners.com/2021/02/05/mgc-pharma-first-cannabis-company-london-stock-exchange/

MGC Pharmaceuticals Ltd (ASX: MXC, ‘MGC’ or ‘the Company’), a European based ‘Seed to Medicine’ bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines, is pleased to announce successful research results from the ongoing pre-clinical research program that supports and directs novel cannabinoid formulations in the development of treatment for glioblastoma multiforme (‘GBM’), the most aggressive, and so far therapeutically resistant, primary
brain tumour.

The cannabinoid formulations used in this collaborative research program are proprietary and are core to the intellectual property of MGC Pharmaceuticals.

Key Highlights
• This pre-clinical research focuses on the development of cannabinoid formulations specifically tailored for the effective treatment of high-grade brain tumours
• Recent data from NIB, conducted on 14 additional GBM tumour tissue samples, support and direct novel cannabinoid formulations in the treatment of glioblastoma
• Results to date on brain tissue samples from a total of 24 patients (including the 10 patients reported on in July 2019) confirm that the cannabinoid preparations can successfully inhibit tumour cell viability and cause a significant percentage of glioblastoma cells to undergo
“programmed cell death” i.e. apoptosis, after a short time following application

Research also shows CBG termination effects specifically on glioblastoma stem cells, which tend to be extremely resistant to irradiation and chemotherapy treatments


https://themarketherald.com.au/mgc-pharmaceuticals-asxmxc-successful-results-from-ongoing-brain-cancer-research-2020-04-22/

"The Company has now passed the 1,000 prescribed products milestone ahead of schedule in Australia and the United Kingdom, through prescriptions issued to more than 500 unique patients."

http://www.aspecthuntley.com.au/docserver/02167030.pdf?fileid=02167030&datedir=20191031&edt=MjAxOS0xMS0wNCsxNDowNTo0Mys0ODArNzUyOTAxK2FuZHJld3dlc3QrcmVkaXJlY3QraHR0cDovL3d3dy5hc3BlY3RodW50bGV5LmNvbS5hdS9pbWFnZXNpZ25hbC9lcnJvcnBhZ2VzL3BkZnRpbWVvdXQuaHRtbCtodHRwOi8vd3d3LmFzcGVjdGh1bnRsZXkuY29tLmF1L2ltYWdlc2lnbmFsL2Vycm9ycGFnZXMvcGRmZGVsYXllZC5qc3A=

'MGC Lands Key Australian Cannabis Licence'

https://thewest.com.au/business/public-companies/mgc-lands-key-australian-cannabis-cultivation-licence-c-138467


Official ASX announcement:

http://www.aspecthuntley.com.au/docserver/02109587.pdf?fileid=02109587&datedir=20190529&edt=MjAxOS0wNS0yOSsxOToyNzozOCs0ODArNzUyOTAxK2FuZHJld3dlc3QrcmVkaXJlY3QraHR0cDovL3d3dy5hc3BlY3RodW50bGV5LmNvbS5hdS9pbWFnZXNpZ25hbC9lcnJvcnBhZ2VzL3BkZnRpbWVvdXQuaHRtbCtodHRwOi8vd3d3LmFzcGVjdGh1bnRsZXkuY29tLmF1L2ltYWdlc2lnbmFsL2Vycm9ycGFnZXMvcGRmZGVsYXllZC5qc3A=

As we progress further into 2019, we’d like to update you on the progress of our MGC Botanic division:

In 2018, our cannabis crop in the Czech Republic delivered 30% more flowers than the 2017 harvest and is being prepared for immediate transportation to its Slovenian extraction facility.

In addition, the Slovenian Ministry of Health has awarded us a permit for the extraction of phytocannabinoids for the creation of MXC’s own proprietary APIs (Active Pharmaceutical Ingredients).

We’re also pleased to report that we have successfully developed a new proprietary genetic strain, MXC-10, containing the highest level of THC (>35%) of any MXC strand launched to date.

The next step for our Botanic division is to begin the process of registering our four unique Cannabis Sativa strains (bred in the University of Slovenia Biotechnical faculty) in Europe for medical purposes — an enormous production and distribution milestone for MGC Pharma.

See the full update here: http://snip.ly/46iz47

"Today we’re pleased to report that three landmark milestones have now been met by MGC Pharma.

1. Our CTN (Clinical Trial Notification) for CogniCann™ into Alzheimer’s and dementia at the University of Notre Dame is now available in the Clinical Trials Repository.

2. We are one of the first EU facilities to be granted a full API extraction permit to develop our own THC, CBD and other Phytocannabinoids for use in CannEpil™, CogniCann™ and future phytomedicines.

3. We have received SME certification from the European Medicines Agency (EMA) for the scientific advice, drug evaluation and registration of CannEpil™, CogniCann™ and additional Phytomedicines that the Company is developing.

These are landmark milestones for the MGC Pharma company and are a testament to the continuous hard work we’re putting in to become a global market leader in phytocannabinoids."

Read the full announcement here: http://snip.ly/bx35d9

Sale is complete.

"We’re pleased to report that the sale of MGC Derma to CannaGlobal has officially reached completion.

We have now been issued shares in CannaGlobal totalling 10% of their outstanding share capital, making us a strategic shareholder in the global business and symbolising a significant milestone for MXC as we can now focus on our corporate strategy of becoming a world-leading, European based bio-pharma company."

Read the full announcement here: http://snip.ly/k453ar

MGC Nutraceuticals website has been updated:

www.mgcnutraceuticals.com


Facebook and Instagram accounts have also been created:

https://www.instagram.com/mgcnutraceuticals/

https://www.facebook.com/MGC-Nutraceuticals-1199013120254983/

CannaGlobal introductory video!

CannaGlobal introductory video